The New England Journal of Medicine published results from a positive Phase 2 clinical trial demonstrating frexalimab significantly slowed disease activity in people with relapsing multiple sclerosis (MS), corresponding to 89% and 79% reduction in new gadolinium-enhancing (GdE) T1 brain…
Gilead Sciences and CymaBay Therapeutics announced today a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion. The addition of CymaBay’s investigational lead product candidate, seladelpar for…
Biogen announced the European Commission (EC) has authorized SKYCLARYS® (omaveloxolone) for the treatment of Friedreich’s ataxia (FA) in adults and adolescents aged 16 years and older. 👉 SKYCLARYS is the first treatment approved within the European Union for this rare,…
Taygun Günay, currently serving as the Senior Vice President and Cluster Head for Russia and CIS at Bayer Consumer Health, has been appointed as the Senior Vice President and Sub Region Head for Eastern Europe, Middle East, Turkey & Africa.…
Among other roles, Kleinemeier was a member of the Executive Board of SAP SE, Walldorf, as Head of SAP Digital Business Services from 2015 to 2020. He has been a member of the Merck Supervisory Board since 2019. The election…
Professor Yasmine Belkaid is a renowned scientist whose research focuses on the relationship between microbes and the immune system. Her varied scientific career, which began at the Institut Pasteur with a PhD in Immunology, has covered fields including parasitology, microbiology,…
Novartis today announced that it has entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys, a Germany-based, global biopharmaceutical company developing innovative medicines in oncology. The acquisition, which is subject to customary closing conditions, including…
Lundbeck today announced the appointment of Dianne Hol to the role of EVP, People & Organization. Dianne will join Lundbeck on 1 April 2024 and will be part of the Executive Management. Dianne will be responsible for driving Lundbeck’s people…
Sanofi today launches ‘Cancer & Work: Acting Together’, a global program to support Sanofi employees whose lives are impacted by cancer and other critical illnesses. This program covers all Sanofi employees in the world if they are diagnosed with cancer…
If approved, PADCEV with KEYTRUDA has the potential to change the treatment paradigm, becoming the first combination treatment to offer an alternative to platinum-containing chemotherapy, the current standard of care in first-line la Ahsan Arozullah, M.D., M.P.H., Senior Vice President,…